US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4673641A
(en)
|
1982-12-16 |
1987-06-16 |
Molecular Genetics Research And Development Limited Partnership |
Co-aggregate purification of proteins
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
EP0206448B1
(fr)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hémoglobine liée à un poly(oxyde d'alkylène)
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1991010741A1
(fr)
|
1990-01-12 |
1991-07-25 |
Cell Genesys, Inc. |
Generation d'anticorps xenogeniques
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
CA2124967C
(fr)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Animaux transgeniques non humains capables de produire des anticorps heterologues
|
ATE222291T1
(de)
|
1992-03-13 |
2002-08-15 |
Organon Teknika Bv |
Epstein-barr-virus verwandte peptide und nukleinsäuresegmenten
|
US5625825A
(en)
|
1993-10-21 |
1997-04-29 |
Lsi Logic Corporation |
Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
|
US5770565A
(en)
|
1994-04-13 |
1998-06-23 |
La Jolla Cancer Research Center |
Peptides for reducing or inhibiting bone resorption
|
US5688781A
(en)
|
1994-08-19 |
1997-11-18 |
Bristol-Myers Squibb Company |
Method for treating vascular leak syndrome
|
AU715621B2
(en)
|
1995-04-06 |
2000-02-03 |
Regeneron Pharmaceuticals, Inc. |
TIE-2 ligands, methods of making and uses thereof
|
SI0833934T2
(sl)
|
1995-06-15 |
2013-04-30 |
Crucell Holland B.V. |
Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
|
US20030040463A1
(en)
|
1996-04-05 |
2003-02-27 |
Wiegand Stanley J. |
TIE-2 ligands, methods of making and uses thereof
|
WO1998018914A1
(fr)
|
1996-10-31 |
1998-05-07 |
Duke University |
Recepteur tie2 soluble
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
US5980929A
(en)
|
1998-03-13 |
1999-11-09 |
Johns Hopkins University, School Of Medicine |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
|
US5919813C1
(en)
|
1998-03-13 |
2002-01-29 |
Univ Johns Hopkins Med |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
|
AR022303A1
(es)
*
|
1999-01-22 |
2002-09-04 |
Lundbeck & Co As H |
Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
ES2199804T3
(es)
|
1999-03-26 |
2004-03-01 |
Regeneron Pharmaceuticals, Inc. |
Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
|
EP1046715A1
(fr)
*
|
1999-04-23 |
2000-10-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Interaction de la protéine vasculaire endothelial tyrosine phosphatase et le récepteur Tie-2 d'angiopoietine
|
AU5062500A
(en)
|
1999-04-26 |
2000-11-10 |
Amersham Pharmacia Biotech Ab |
Primers for identifying typing or classifying nucleic acids
|
CA2372053C
(fr)
|
1999-04-28 |
2008-09-02 |
Board Of Regents, The University Of Texas System |
Compositions et procedes de traitement du cancer par inhibition selective de vegf
|
AU5147700A
(en)
|
1999-05-19 |
2000-12-05 |
Amgen, Inc. |
Crystal of a lymphocyte kinase-ligand complex and methods of use
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
CA2382789A1
(fr)
|
1999-08-27 |
2001-03-08 |
Sugen, Inc. |
Mimetiques phosphates et procedes de traitement utilisant des inhibiteurs de phosphatase
|
JP2003525054A
(ja)
*
|
2000-02-29 |
2003-08-26 |
バーンズ − ジューウィッシュ・ホスピタル |
受容体タイプのプロテインチロシンホスファターゼβ/ζによるプレイオトロフィンシグナリングの変調
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
KR20080068151A
(ko)
|
2000-06-23 |
2008-07-22 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
VEGF/VEGF 수용체 및 안지오포이에틴/Tie수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
|
US6316109B1
(en)
|
2000-09-21 |
2001-11-13 |
Ppg Industries Ohio, Inc. |
Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
|
CZ2003788A3
(cs)
|
2000-09-27 |
2003-08-13 |
The Procter & Gamble Company |
Ligandy melanokortinového receptoru
|
WO2002076510A1
(fr)
*
|
2001-03-23 |
2002-10-03 |
Agy Therapeutics |
Utilisation de cibles biomoleculaires dans le traitement et la visualisation de tumeurs cerebrales
|
US6455026B1
(en)
*
|
2001-03-23 |
2002-09-24 |
Agy Therapeutics, Inc. |
Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
|
CN1318093C
(zh)
|
2001-09-28 |
2007-05-30 |
参天制药株式会社 |
含与聚乙二醇结合的药物的眼组织注射剂
|
US20050260132A1
(en)
*
|
2001-10-17 |
2005-11-24 |
Daniel Chin |
Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
|
WO2003034990A2
(fr)
|
2001-10-25 |
2003-05-01 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietines et methodes d'utilisation
|
EP1450852B1
(fr)
*
|
2001-12-04 |
2007-01-17 |
DeveloGen Aktiengesellschaft |
Acides nucleiques et peptides de ptp10d intervenant dans la regulation de l'homeostasie energetique
|
US20030158083A1
(en)
|
2002-02-08 |
2003-08-21 |
The Procter & Gamble Company |
Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
|
US20030215899A1
(en)
|
2002-02-13 |
2003-11-20 |
Ceptyr, Inc. |
Reversible oxidation of protein tyrosine phosphatases
|
AU2003229627A1
(en)
|
2002-04-08 |
2003-10-20 |
Max-Planck-Gesellschaft Zur |
Ve-ptp as regulator of ve-cadherin mediated processes or disorders
|
IL164799A0
(en)
|
2002-04-25 |
2005-12-18 |
Univ Connecticut |
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
|
US20040023880A1
(en)
|
2002-05-03 |
2004-02-05 |
Gale Nicholas W. |
Methods of inducing formation of functional and organized lymphatic vessels
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
US20040167183A1
(en)
|
2003-02-20 |
2004-08-26 |
The Procter & Gamble Company |
Phenethylamino sulfamic acids
|
JPWO2004106542A1
(ja)
|
2003-05-29 |
2006-07-20 |
三共株式会社 |
インスリン抵抗性改善剤及びそのスクリーニング方法
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050059639A1
(en)
|
2003-09-11 |
2005-03-17 |
Wei Edward T. |
Ophthalmic compositions and method for treating eye discomfort and pain
|
US20050158320A1
(en)
|
2003-11-12 |
2005-07-21 |
Nichols M. J. |
Combinations for the treatment of proliferative diseases
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
SI2298744T1
(sl)
|
2004-03-15 |
2013-10-30 |
Janssen Pharmaceutica N.V. |
Modulatorji opioidnega receptorja
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
BRPI0513534A
(pt)
|
2004-07-20 |
2008-05-06 |
Genentech Inc |
inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
|
US7691365B2
(en)
|
2004-09-28 |
2010-04-06 |
Aprogen, Inc. |
Methods of using chimeric coiled coil molecule to treat ischemic disease
|
EP2284194A1
(fr)
|
2004-12-21 |
2011-02-16 |
AstraZeneca AB |
Anticorps dirigés contre l'Angiopoiétine 2 et leurs utilisations
|
CA2599606A1
(fr)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Agents de liaison bispecifiques utilises pour moduler une activite biologique
|
US20120237442A1
(en)
|
2005-04-06 |
2012-09-20 |
Ibc Pharmaceuticals, Inc. |
Design and Construction of Novel Multivalent Antibodies
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
US7893040B2
(en)
|
2005-07-22 |
2011-02-22 |
Oculis Ehf |
Cyclodextrin nanotechnology for ophthalmic drug delivery
|
KR200400225Y1
(ko)
|
2005-08-02 |
2005-11-03 |
김기룡 |
자동복귀 기능을 가지는 도로교통표지판 어셈브리
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
JP2009510102A
(ja)
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
免疫調節組成物およびその使用
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
FR2894225B1
(fr)
|
2005-12-07 |
2008-01-11 |
Airbus France Sa Sa |
Mur de cloisonnement pour carenage ventral d'aeronef et aeronef muni d'un carenage ventral
|
FR2894536B1
(fr)
|
2005-12-09 |
2009-10-09 |
Holophane Sa Sa |
Retroviseur de vehicule automobile
|
FR2894517B1
(fr)
|
2005-12-09 |
2010-01-08 |
Renault |
Systeme de surveillance de la pression des pneumatiques d'un vehicule automobile et procede pour etablir un diagnostic au moyen de ce systeme
|
WO2007068895A1
(fr)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du vegf-a et/ou du kdr et/ou du fltl pour le traitement du cancer
|
WO2007087457A2
(fr)
|
2006-01-30 |
2007-08-02 |
(Osi) Eyetech, Inc. |
Polytherapie destinee au traitement de troubles neovasculaires
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
CA3148917A1
(fr)
|
2006-03-08 |
2007-09-13 |
Archemix Llc |
Aptameres de liaison du complement et agents anti-c5 utiles dans le traitement de troubles oculaires
|
CA2647282A1
(fr)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Polytherapie a base d'un anticorps anti-ctla4
|
MX2008012991A
(es)
|
2006-04-07 |
2008-10-17 |
Procter & Gamble |
Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
|
ZA200807978B
(en)
|
2006-04-07 |
2009-08-26 |
Procter & Gamble |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPBETA) and uses thereof
|
EP2029103A2
(fr)
|
2006-06-16 |
2009-03-04 |
Regeneron Pharmaceuticals, Inc. |
Formulations antagonistes du vegf appropriées à une administration intravitréenne
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US20130023542A1
(en)
|
2006-06-27 |
2013-01-24 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
RU2435763C2
(ru)
|
2006-06-27 |
2011-12-10 |
Дзе Проктер Энд Гэмбл Компани |
Ингибиторы тирозинфосфатазы белка человека и способы применения
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
CN101506180B
(zh)
|
2006-06-27 |
2013-10-30 |
艾尔普罗医疗有限公司 |
人蛋白酪氨酸磷酸酶抑制剂及使用方法
|
US7733204B2
(en)
|
2006-06-29 |
2010-06-08 |
Intel Corporation |
Configurable multiphase coupled magnetic structure
|
IL176666A0
(en)
|
2006-07-02 |
2006-10-31 |
Rol Profil Ltd |
Roller shutter assembly
|
IL176685A
(en)
|
2006-07-03 |
2011-02-28 |
Eci Telecom Dnd Inc |
Method for performing a system shutdown
|
IL176712A0
(en)
|
2006-07-05 |
2007-10-31 |
Michael Cohen Alloro |
Medication dispenser
|
EP2076290B1
(fr)
|
2006-10-27 |
2016-12-14 |
Sunnybrook Health Sciences Center |
Agonistes tie 2 multimères et leurs utilisations dans la stimulation de l'angiogenèse
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
BRPI0809678A2
(pt)
|
2007-04-03 |
2014-10-07 |
Novartis Ag |
Métodos
|
US20100256147A1
(en)
|
2007-04-13 |
2010-10-07 |
Hangauer Jr David G |
Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
WO2009003110A2
(fr)
|
2007-06-26 |
2008-12-31 |
Children's Medical Center Corporation |
Polymersomes inhibiteurs de metap-2 destinés à l'administration thérapeutique
|
ES2540854T3
(es)
|
2007-06-29 |
2015-07-14 |
Merck Sharp & Dohme Corp. |
Usos de antagonistas MDL-1
|
EP2212432A4
(fr)
|
2007-10-22 |
2011-10-19 |
Schering Corp |
Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
|
EP2280601A4
(fr)
|
2008-02-21 |
2012-08-29 |
Sequoia Pharmaceuticals Inc |
Inhibiteurs aminoacides du cytochrome p450
|
US8293714B2
(en)
|
2008-05-05 |
2012-10-23 |
Covx Technology Ireland, Ltd. |
Anti-angiogenic compounds
|
CA3020290A1
(fr)
|
2008-06-25 |
2009-12-30 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Anticorps stables et solubles inhibant le vegf
|
US7769557B2
(en)
*
|
2008-07-01 |
2010-08-03 |
Honeywell International Inc. |
Multi-gas flow sensor with gas specific calibration capability
|
WO2010060748A1
(fr)
|
2008-11-03 |
2010-06-03 |
Molecular Partners Ag |
Protéines de liaison inhibant l’interaction du récepteur vegf-a
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
CN108635350A
(zh)
|
2009-01-12 |
2018-10-12 |
爱尔皮奥治疗有限公司 |
治疗血管渗漏综合征的方法
|
BRPI1012302A2
(pt)
|
2009-03-03 |
2015-09-22 |
Alcon Res Ltd |
composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho
|
WO2010101971A1
(fr)
|
2009-03-03 |
2010-09-10 |
Alcon Research, Ltd. |
Composition pharmaceutique pour l'administration à l'oeil de composés inhibant les récepteurs tyrosine kinase (rtki)
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
CA2748765C
(fr)
|
2009-07-06 |
2014-07-22 |
Akebia Therapeutics Inc. |
Composes, compositions et methodes de prevention de la metastase cancereuse
|
AU2010314976B2
(en)
|
2009-11-06 |
2014-03-06 |
Aerpio Therapeutics Inc. |
Prolyl hydroxylase inhibitors
|
EP3511023A1
(fr)
|
2009-12-02 |
2019-07-17 |
Imaginab, Inc. |
Minicorps j591 et cys-diacorps pour cibler l'antigène membranaire spécifique de la prostate humaine (psma) et leurs procédés d'utilisation
|
BR112012017071A2
(pt)
|
2010-01-14 |
2016-04-12 |
Univ Nagoya City |
produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular
|
IL300733A
(en)
|
2010-03-05 |
2023-04-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeting immune modulation
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
EP3311835B1
(fr)
|
2010-07-12 |
2021-03-24 |
Threshold Pharmaceuticals Inc. |
Administration de promédicaments activés par hypoxie et d'agents anti-angiogéniques pour le traitement du cancer
|
CA2818215C
(fr)
|
2010-10-07 |
2015-07-21 |
Aerpio Therapeutics Inc. |
Compositions et methodes de traitement d'un oedeme oculaire, de neovascularisation et de maladies associees
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
EP2857032A3
(fr)
|
2010-12-02 |
2015-07-15 |
Maruzen Pharmaceuticals Co., Ltd. |
Activateur tie2, inhibiteur de facteur de croissance endothélial vasculaire (vegf), agent anti-angiogénique, agent de maturation des vaisseaux sanguins, agent pour normaliser des vaisseaux sanguins, agent de stabilisation de vaisseaux sanguins et composition pharmaceutique
|
KR20210030510A
(ko)
|
2011-01-13 |
2021-03-17 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
MX363351B
(es)
|
2011-10-13 |
2019-03-20 |
Aerpio Therapeutics Inc |
Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
|
US8999325B2
(en)
*
|
2011-10-13 |
2015-04-07 |
Aerpio Therapeutics, Inc |
Treatment of ocular disease
|
BR112014010532A2
(pt)
|
2011-11-03 |
2017-04-18 |
Tolera Therapeutics Inc |
anticorpo e métodos para inibição seletiva de respostas de célula-t
|
US20130190324A1
(en)
|
2011-12-23 |
2013-07-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Topical ocular drug delivery
|
AU2013245630A1
(en)
|
2012-04-13 |
2014-10-30 |
The Johns Hopkins University |
Treatment of ischemic retinopathies
|
EP3646880A1
(fr)
|
2012-05-07 |
2020-05-06 |
Allergan, Inc. |
Procédé de traitement d'amd chez des patients souffrant d'un état réfractaire à la thérapie anti-vegf
|
JP6154900B2
(ja)
|
2012-07-13 |
2017-06-28 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異性抗vegf/抗ang−2抗体及び眼血管疾患の処置におけるそれらの使用
|
MX360824B
(es)
|
2012-07-31 |
2018-11-15 |
Univ Texas |
Una combinación para inducir la formación de células beta de células de mamífero y uso de la misma.
|
EP2890389A1
(fr)
|
2012-08-28 |
2015-07-08 |
Novartis AG |
Utilisation d'un antagoniste du vegf dans le traitement de maladies de prolifération vasculaire oculaire
|
SG11201501914XA
(en)
|
2012-10-11 |
2015-05-28 |
Ascendis Pharma Ophthalmology Division As |
Vegf neutralizing prodrugs for the treatment of ocular conditions
|
BR112015010566A2
(pt)
|
2012-11-08 |
2017-07-11 |
Clearside Biomedical Inc |
métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
|
EP2922572A1
(fr)
|
2012-11-23 |
2015-09-30 |
AB Science |
Utilisation d'inhibiteurs/activateurs à petite molécule en combinaison avec des analogues de (désoxy)nucléoside ou de (désoxy)nucléotide pour le traitement du cancer et de malignités hématologiques ou d'infections virales
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
GB2516561B
(en)
|
2013-03-15 |
2016-03-09 |
Aerpio Therapeutics Inc |
Compositions, formulations and methods for treating ocular diseases
|
EP2983695B1
(fr)
|
2013-04-11 |
2019-05-29 |
Sunnybrook Research Institute |
Méthodes, utilisations et compositions d'agonistes de tie2
|
WO2014203183A1
(fr)
|
2013-06-20 |
2014-12-24 |
Novartis Ag |
Utilisation d'un antagoniste du vegf dans le traitement d'un œdème maculaire
|
EP3010525A1
(fr)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Utilisation d'un antagoniste du vegf dans le traitement de la néovascularisation choroïdienne
|
WO2015002893A1
(fr)
|
2013-07-02 |
2015-01-08 |
The Trustees Of Columbia University In The City Of New York |
Élimination de lipides bioactifs de structures membranaires au moyen de cyclodextrines
|
CN105377891A
(zh)
|
2013-07-11 |
2016-03-02 |
诺华股份有限公司 |
Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
|
US20160159893A1
(en)
|
2013-07-11 |
2016-06-09 |
Gabriela Burian |
Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
|
EP2835380B2
(fr)
|
2013-07-29 |
2021-04-07 |
Samsung Electronics Co., Ltd |
Procédé de blocage de fuite vasculaire utilisant un anticorps anti-ANG2
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
RU2727022C2
(ru)
|
2013-10-01 |
2020-07-17 |
Сфинготек Гмбх |
Способ прогнозирования риска возникновения тяжелых нежелательных сердечных явлений
|
EP3057990B1
(fr)
|
2013-10-18 |
2019-09-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions comprenant une combinaison d'antagoniste du vegf et d'anticorps anti-ctla-4
|
SI3062811T1
(sl)
|
2013-11-01 |
2020-07-31 |
Regeneron Pharmaceuticals, Inc. |
Posegi na podlagi angiopoietina za zdravljenje cerebralne malarije
|
US20150126458A1
(en)
|
2013-11-05 |
2015-05-07 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
RU2019118984A
(ru)
|
2014-01-10 |
2019-08-06 |
Анаптисбайо, Инк. |
Антитела, направленные против интерлейкина-33 (il-33)
|
EP3116503A4
(fr)
|
2014-03-14 |
2017-08-23 |
Aerpio Therapeutics, Inc. |
Inhibiteurs de hptp-bêta
|
JP2015199733A
(ja)
|
2014-04-04 |
2015-11-12 |
国立大学法人東北大学 |
眼圧降下剤
|
US9719135B2
(en)
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
US9539245B2
(en)
|
2014-08-07 |
2017-01-10 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of Tie-2
|
TW201619194A
(zh)
|
2014-09-16 |
2016-06-01 |
歐把科學股份有限公司 |
特異性結合至人類vasa蛋白質的抗體、抗體製劑、經分離核酸分子、細胞及分離表現vasa蛋白質的細胞的方法
|
US20160082129A1
(en)
|
2014-09-24 |
2016-03-24 |
Aerpio Therapeutics, Inc. |
VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
|
TWI705827B
(zh)
|
2014-11-07 |
2020-10-01 |
瑞士商諾華公司 |
治療眼部疾病之方法
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
CA2970315C
(fr)
|
2014-12-11 |
2023-08-22 |
Bayer Healthcare Llc |
Utilisation d'agents anti-vegf pour traiter les lesions chez les patients atteints de degenerescence maculaire
|
WO2016115092A1
(fr)
|
2015-01-12 |
2016-07-21 |
La Jolla Institute For Allergy And Immunology |
Procédés de ciblage de mécanisme vasculaire hôte à des fins de protection thérapeutique contre la fièvre hémorragique
|
BR112017020986A2
(pt)
|
2015-04-02 |
2018-08-14 |
Molecular Partners Ag. |
proteínas de ligação recombinantes e seu uso
|
EP3341021A4
(fr)
|
2015-08-27 |
2019-03-13 |
Celldex Therapeutics, Inc. |
Anticorps anti-alk et leurs procédés d'utilisation
|
TWI748962B
(zh)
|
2015-09-23 |
2021-12-11 |
美商建南德克公司 |
抗vegf抗體之最佳化變異體
|
JP6959924B2
(ja)
|
2015-09-23 |
2021-11-05 |
エアーピオ ファーマシューティカルズ, インコーポレイテッド |
Tie−2の活性化物質を用いる眼内圧を処置する方法
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
JP6983824B2
(ja)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規抗体フォーマット
|
CA3030298A1
(fr)
*
|
2016-07-20 |
2018-01-25 |
Aerpio Therapeutics, Inc. |
Anticorps monoclonaux humanises ciblant ve-ptp (hptp-ss)
|
CN110177563A
(zh)
|
2016-10-04 |
2019-08-27 |
阿斯克雷佩西治疗公司 |
用于激活tie2信号传导的化合物和方法
|
IT201600120314A1
(it)
|
2016-11-28 |
2018-05-28 |
Nuovo Pignone Tecnologie Srl |
Turbo-compressore e metodo di funzionamento di un turbo-compressore
|
US10426817B2
(en)
|
2017-01-24 |
2019-10-01 |
Macregen, Inc. |
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
|
EP3630148A4
(fr)
|
2017-05-26 |
2021-06-16 |
The Johns Hopkins University |
Pièges d'anticorps-ligand multifonctionnels pour moduler la tolérance immunitaire
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
CN107602702A
(zh)
|
2017-09-22 |
2018-01-19 |
生标(上海)医疗器械科技有限公司 |
一种同时靶向人p185和血管内皮生长因子的抗体及其应用
|
LT3716992T
(lt)
|
2017-11-30 |
2022-09-12 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonisto panaudojimas akių angiogeninių sutrikimų gydymui
|
EP3758735B1
(fr)
|
2018-02-28 |
2023-12-13 |
AP Biosciences, Inc. |
Protéines bifonctionnelles combinant un blocage des points de contrôle pour une thérapie ciblée
|
AU2019235577B2
(en)
|
2018-03-16 |
2021-09-30 |
Novartis Ag |
Methods for treating ocular diseases
|
US10276202B1
(en)
|
2018-04-23 |
2019-04-30 |
Western Digital Technologies, Inc. |
Heat-assisted magnetic recording (HAMR) medium with rhodium or rhodium-based alloy heat-sink layer
|
WO2019217927A1
(fr)
|
2018-05-10 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
|
CA3100349A1
(fr)
|
2018-05-17 |
2019-11-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition de recepteur par recrutement de phosphatases
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
WO2020068653A1
(fr)
|
2018-09-24 |
2020-04-02 |
Aerpio Pharmaceuticals, Inc. |
ANTICORPS MULTISPÉCIFIQUES CIBLANT HPTP- β (VE-PTP) ET VEGF
|